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The seven-transmembrane (7TM) G-protein-coupled neuroendocrine receptors VPAC1 (HGNC approved gene symbol VIPR1) and VPAC2
(HGNC approved gene symbol VIPR2) are expressed in different tissues and involved in the regulation of important biological functions. We now
report the identification and characterization of novel five-transmembrane(5TM) forms of both human VPAC1 and human VPAC2. These
alternatively spliced variant mRNAs result from the skipping of exons 10/11, spanning the third intracellular loop, the fourth extracellular loop,
and the transmembrane regions 6 and 7, producing in-frame 5TM receptors predicted to lack a G-protein-binding motif. RT-PCR showed that
these 5TM receptors are differentially expressed in transformed and normal cells. Translation of the 5TM protein was demonstrated by transfection
and expression in CHO cells. Following agonist stimulation, differential signaling of the 7TM versus 5TM forms was shown both for the
activation of adenylate cyclase and for tyrosine phosphorylation. The identification of these splice variants in various cells and their expression
and differential signal transduction compared to the 7TM form suggest that these novel receptors have biological relevance.
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adenylate cyclase-activating polypeptide receptor family
consists of three receptors, PAC1 (HGNC approved gene
symbol ADCYAP1R1), VPAC1, and VPAC2 [1,2]. These
receptors belong to the class II subfamily of the seven-
transmembrane (7TM) G-protein-coupled receptor (GPCR)
superfamily [1,2]. VPAC1 was first cloned from a rat lung
cDNA library by cross-hybridization with a secretin receptor
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doi:10.1016/j.ygeno.2006.07.008the HT29 human colonic adenocarcinoma cell line library [4].
The VPAC1 receptor comprises 457 amino acids and its gene
spans 22 kb, which is composed of 13 exons ranging in size
from 42 to 1400 bp [4]. VPAC1 is evolutionarily conserved
and structurally characterized by its 7TM domains with an
extracellular N-terminus and a cytoplasmic C-terminus [5].
VPAC1 is found in certain regions of the brain, notably the
piriform cortex, the septal nucleus, and the hippocampal
formation [6,7]. VPAC1 is also a predominant receptor
expressed on other cells and tissues, particularly on resting T
lymphocytes and peripheral blood monocytes [8–10]. In
addition, studies have shown that tumor-derived breast and
intestinal cell lines, as well as some malignant T
lymphoblastic cell lines, exhibit VPAC1 mRNA in large
amounts [10–12]. Furthermore, our laboratory has recently
792 P.B. Bokaei et al. / Genomics 88 (2006) 791–800shown that VPAC1 binds to human immunodeficiency virus
type 1 (HIV-1) to transduce an intracellular signal that
results in facilitation of HIV-1 productive infection [13].
The VPAC2 receptor was initially cloned from a rat pituitary
cDNA library [14] and subsequently from a human placenta
cDNA library [15]. VPAC2 is present in human skeletal muscle,
intestine, and brain, especially in the thalamus and cerebral
cortex [16,17]. VPAC2 is encoded by 13 exons and the human
gene spans 117 kb [15]. VPAC2 is expressed more selectively
than is VPAC1. VPAC2 is found at very low levels on resting
monocytes and T cells but its expression is increased after
activation of these cells [10].
Significant differences exist between VPAC1 and VPAC2,
both in structure and in function [18,19]. Indeed, there are a
number of reports indicating opposing functions for these two
receptors [20,21]. Recently, we have shown that VPAC2
stimulation by specific agonists dramatically inhibits HIV-1
productive infection [22]. The opposite effect is observed afterFig. 1. Sequence alignment of seven- and five-traVPAC1 stimulation, which causes an increase in HIV-1
productive infection [13].
In this study, we describe the identification, isolation, and
characterization of two novel human 5TM VPAC receptor
isoforms, one of VPAC1 and one of VPAC2. This is the first
description of these isoforms in human cells. These splice-
variant VPAC isoforms are differentially expressed in normal
human primary peripheral blood mononuclear and cord blood
cells and in malignant hematopoietic- and epithelial-derived
cancer cell lines. Using transfection, we confirmed that the 5TM
isoform, predicted by sequence analysis to lack a G-protein-
binding site, can be translated and has significantly decreased
ability to increase intracellular cAMP in response to vasoactive
intestinal peptide (VIP) and secretin compared to cells
transfected to express the 7TM receptor. However, despite a
lack of G protein binding and adenylate cyclase activation,
stimulation of the 5TM isoform was, nonetheless, able to acti-
vate protein tyrosine kinase activity that showed a differentialnsmembrane VPAC1 and VPAC2 receptors.
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pared to the 7TM receptor. These results suggest that both
isoforms of VPAC1 and VPAC2 would have biological
relevance.
Results
Sequence alignment of VPAC1 and VPAC2 isoforms
In our effort to clone full-length human VPAC1 from
normal peripheral blood mononuclear cells (PBMCs) and
VPAC2 from the human Sup-T1 cell line, we unexpectedly
identified splice variant receptor transcripts. These variant
receptors of VPAC1 and VPAC2, bearing 264- and 222-bp
deletions, respectively, showed an open reading frame that
would encode receptors lacking, respectively, 88 and 74
amino acid residues (Fig. 1). Interestingly, analysis of the
deduced amino acid sequences revealed that the truncated
VPAC1 and VPAC2 isoforms lack the regions in the third
intracellular loop, the fourth extracellular loop, and TM6–7
(Figs. 1 and 2A). These alternative splicing events result in
transcripts that encode a putative five-transmembrane domain
form (Fig. 2B).
VPAC1 and VPAC2 expression in normal and malignant cells
It has been reported that 7TM VPAC1 and VPAC2 are, or
can be induced to be, expressed in most human tissues
[23,24]. As the identification of human 5TM isoforms has
never been reported, we examined the expression of 7TM
compared to 5TM VPAC1 and VPAC2 isoforms in differentFig. 2. (A) Deletions of 7TM VPAC1 and VPAC2 nucleotides that result in 5TM trun
Schematic representation of the 7TM and 5TM VPAC1 and VPAC2 receptors. The d
results in the 5TM truncated isoforms. Light shading indicates deletions. The arrowcells. A strategy using specific primers designed to amplify
both 5TM and 7TM VPAC1 isoforms (Fig. 3A) was
confirmed using Hut78 cells (Fig. 3B). Using this RT-PCR
demonstrated differential patterns of mRNA expression in
different cells. In normal, nonactivated PBMCs, and malig-
nant cell lines Hut78, Raji, and Colo205, expression of both
isoforms was evident. However, in normal cord blood
PBMCs and malignant CaCo2 and transformed 293 cells,
only the 7TM form of VPAC1 was found. Furthermore, the T
cell leukemia-derived Kit225 and ACHN kidney-derived cells
do not express either VPAC1 isoform.
A strategy using nested RT-PCR (Fig. 4A) was optimized
and used to examine the expression of 5TM and 7TM VPAC2
receptor isoforms. The ability of the RT-PCR to amplify both
transcripts was confirmed using Sup-T1 cells (Fig. 4B). The
results reveal limited expression of the 5TM isoform but also
differential expression of the VPAC2 mRNA (Fig. 4C). Normal
nonactivated PBMCs express low levels of 7TM VPAC2
mRNA as previously published [9,10]; however, these cells do
not express the 5TM isoform (Fig. 4C). Following activation
with PHA/IL-2 or with PHA alone, the 7TM isoform of VPAC2
shows increased expression and the 5TM isoform is now also
expressed; indeed, the only other cells tested that expressed
5TM VPAC2 transcripts were Sup-T1 cells, the original cells
from which the two isoforms were cloned. Neither Daudi nor
THP-1 cells express either transcript. The other cell lines
examined expressed only the 7TM VPAC2. These results were
confirmed by Southern blot, which showed hybridization of a
full-length VPAC2 radioactive probe to only those bands
corresponding to the 5TM and 7TM positive (+ve) controls
(Fig. 4D).cated isoforms. The deleted residues in the mutants are indicated by dashes. (B)
eletion in the third intracellular loop, the fourth extracellular loop, and TM6–7
s indicate the connecting point of TM5 to the C-terminus.
Fig. 3. Differential expression of 7TM and 5TM VPAC1 transcripts in normal and malignant cells. (A) Schematic representation of the structure of the full-length
VPAC1 mRNA showing the locations of specific primer pairs for amplification of the VPAC1 cDNA (see Materials and methods). The shaded area represents the
deletion that creates the 5TM isoform. (B) RT-PCR result using the primer pair indicated in A to amplify both 7TM and 5TM VPAC1 isoforms from Hut78 cells. (C)
Detection of VPAC1 transcripts in different cells. Results are from normal human PBMCs, normal cord blood mononuclear cells (Cord Blood), epithelial cancer-
derived cell lines (Colo205, CaCo2, ACHN), a transformed epithelial cell line (293), and hematopoietic cancer-derived cell lines (Raji, Hut78, and Kit225). Positive
controls consisted of Hut78 and cDNA for the cloned either 5TM or 7TM VPAC1. Negative control was water.
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Because it has been reported that certain mutations in the
GPCR may result in poor protein expression and/or impair the
stability of the receptor on themembrane [25,26], it is important to
show that the novel alternative splicing we have documented
results in protein production. Due to a lack of potent antibodies to
VPAC receptors, to address this issue, we used transfection of
CHO cells with VPAC1 5TM and 7TM cDNA in pcDNA3.1,
which contains an Xpress tag so as to be able to monitor the
protein expression by immunoprecipitation of metabolically
labeled protein. Fig. 5 shows our results that indicate the trans-
lation of these isoforms to the predicted molecular sized proteins
and support previous reports of production of other cell surface
proteins having mutations encoding a truncated receptor [27,28].
Functionality of VPAC isoforms
GPCR responses are critically dependent on the functional
interaction between the receptor and its ligand and the
subsequent G-protein-dependent activation. These interactionslead to the generation of a signaling pathway(s) that ultimately
leads to a specific cell function. To examine whether 5TM
VPAC isoforms retain functionality, particularly as they are
predicted by sequence analyses to lack a G-protein-binding site,
we compared the abilities of the 7TM and 5TM isoforms to
induce increased production of cAMP and also examined their
ability to activate tyrosine kinases. The response to VIP caused
an approximately fourfold increase in cAMP production in
transfected CHO cells with 7TM VPAC1 compared to empty-
vector control. Response to VIP by 5TM-transfected cells did
not result in an increase in cAMP (Fig. 6A). Receptor-mediated
cellular responses to secretin were also tested and revealed
results similar to those obtained for VIP (Fig. 6A).
A series of experiments was next performed to evaluate
tyrosine kinase activation following VIP or secretin stimulation
of 7TM and 5TM VPAC1 isoforms. In this regard, transfected
CHO cells were serum starved overnight and then stimulated
with 50 μM VIP or secretin for 30 min at 37°C. Cells were
washed with PBS and lysed in radioimmunoprecipitation assay
(RIPA) lysis buffer. Although no differences in phosphorylation
between the 5TM- and the 7TM-transfected cells was apparent
Fig. 4. Differential expression of 7TM and 5TMVPAC2 transcripts in normal and malignant cells. (A) Schematic representation of the structure of the full-length VPAC2
mRNA showing the locations of specific primer pairs for first- and second-round amplification of the VPAC2 cDNA. The shaded area represents the deletion that creates the
5TM isoform (seeMaterials andmethods). (B)RT-PCR result using the primer pairs indicated in (A) to amplify both 7TMand 5TMVPAC2 isoforms fromSup-T1 cells. (C)
Detection of VPAC2 transcripts in different cells. Results are from normal human PBMCs, a transformed epithelial cell line (293), and hematopoietic cancer-derived cell
lines (Sup-T1, Jurkat, Daudi, Raji, and THP-1). Positive controls consisted of Sup-T1 and cDNA for the cloned either 5TMor 7TMVPAC2.Negative control waswater. RT-
PCR for protein phosphatase-1 (PP-1) was used as a housekeeping gene control for mRNA quality. (D) Southern blot analysis of RT-PCR results from (C).
795P.B. Bokaei et al. / Genomics 88 (2006) 791–800after stimulation with VIP for 30 min, both showed increased
phosphorylation after stimulation compared to empty vector
control. The lack of differential tyrosine phosphorylation may
be due to some cross-reactivity of the VIP with endogenous
VPAC2 on these cells. In contrast to stimulation with VIP,
Western blot analysis of phosphotyrosine-containing proteins
after 30 min stimulation with secretin showed differential
tyrosine kinase activation (Fig. 6B). Proteins of approximately
50 and 60 kDa showed no increased phosphorylation after
secretin stimulation in the 5TM- compared to the 7TM-
transfected cells, while proteins of approximate molecular
sizes of 30 and 38 kDa showed increased phosphorylation
compared to 7TM-transfected cells. Although the identity ofthese phosphorylated proteins remains to be determined, it can
be speculated that these differences in tyrosine phosphorylation
may lead to generation of a different signaling pathway(s) and
that this differential tyrosine phosphorylation may lead to
unique cell activity or function. Further investigations are
necessary to elucidate the specific signaling pathways following
activation of the different VPAC receptor isoforms.
Discussion
Different isoforms of GPCR have been previously identified
for a number of receptors. In one report, identification and
characterization of a 5TM domain variant isoform of the NTS2
Fig. 5. Expression of VPAC1 7TM and 5TM protein isoforms in CHO cells.
CHO cells transfected with pcDNA3.1 containing cDNA to express either 7TM
or 5TM VPAC1 were identified by autofluorography after 35S metabolic
labeling, immunoprecipitation with anti-Xpress antibody, and SDS–PAGE.
Lane 1 represents CHO cells transfected with empty pcDNA3.1 vector. Lane 2
shows CHO cells transfected with full-length cDNA VPAC1 5TM isoform in
pcDNA 3.1 (39 kDa). Lane 3 shows CHO cells transfected with full-length 7TM
VPAC1 cDNA in pcDNA3.1 (53 kDa).
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described [29]. These investigators demonstrated that alter-
native splicing of the rat NTS2 receptor gene generated a 5TM
domain variant (vNTS2) that is coexpressed with the full-length
NTS2 receptor throughout the brain and spinal cord. These
findings suggested that the rat vNTS2 is a functional receptor
that may play a role in NT signaling in the mammalian central
nervous system. In another study, 5TM mutants of the
chemokine receptors CCR5 and CXCR4 were reported [30].
It was found that 5TM isoforms were produced by the N-
terminal segment connecting directly to TM3 as a result of a
deletion of TM1–2 and the first intracellular and extracellular
loops. In this study it was also shown that the 5TM CCR5 and
CXCR4 isoforms functioned as normal chemokine receptors in
mediating different cell function [30]. It was concluded that in
the case of CCR5 and CXCR4, 5TM isoforms appear to meet
the minimum structural requirements for a functional GPCR.
Importantly, investigators have previously reported splice
variants of the VPAC family member receptor PAC1 [31–33].
In one report [31], splice variants of PAC1 that exhibited altered
adenylate cyclase stimulation and differential abundance were
identified in the frog. In another study [32], Chaudhary and
Baumann found PAC1 splice variants, but not VPAC2 variants,
in the rat brain. Stimulation of the PAC1 variants with PACAP
indicated similar potency of these variant receptors. However,
in a recent study [33], variants of PAC1 were found in human
neuroblastoma cells that demonstrated differential signaling and
the authors concluded that the variant PAC1 receptors have an
important role in the developing nervous system.
Although there have not been any reports until our work of
splice variants of human VPAC1 or VPAC2, an isoform of theVPAC2 receptor has been previously described in mouse [34].
This VPAC2 receptor isoform was identified in immune cells
and shown to have a deletion in the carboxyl-terminal end of the
seventh transmembrane domain. These investigators also
showed that wild-type and the deletion variant VPAC2 bound
the same amount of 125I-VIP with similar affinity. However,
unlike wild-type VPAC2, the deletion variant VPAC2 did not
transduce VIP-elicited increases in intracellular concentrations
of cAMP. It was concluded that a natural deletion of a part of the
last transmembrane domain of mouse VPAC2 abrogates
signaling functions. Recently, however, this group has shown
a differential signaling pathway for wild-type compared to the
deletion variant of VPAC2 [35]. Using production of IL-4, they
reported that exogenous VIP increases IL-4 production from
wild-type VPAC2 transfectants, but decreased IL-4 production
when using the deletion variant VPAC2 transfectants [35]. Data
also supported their conclusion that the ratio of expression of
these two forms of VPAC2 contributes to the overall agonist
effect and that these two VPAC2 receptor isoforms have
opposing functions and can compete with each other in the
production of IL-4.
In our study, we have detected two naturally occurring
human 5TM isoforms of VPAC receptors that are differentially
expressed in different human cell types. Several distinct modes
of GPCR ligand binding have been observed in which any
truncation of the GPCR protein could influence ligand binding
and thus affect signaling pathways that could result in various
and specific functional activities [36,37]. Therefore, we
investigated and compared the expression and response to
ligand of the predicted 5TM VPAC isoforms to those of their
7TM counterpart. Showing that both 5TM and 7TM transcripts
are found differentially expressed in both transformed and
normal cell types suggests that expression of these proteins may
have biological relevance.
We predicted from sequence analyses that the 5TM isoforms
would not activate G proteins but that they may, nevertheless,
transduce a signal when stimulated with ligand. As the 5TM
isoforms for both VPAC1 and VPAC2 have similar structures,
we used only VPAC1 to examine the functionality of these 5TM
isoforms. In this regard, we investigated the ability of VIP and
secretin to activate adenylate cyclase and induce cAMP
production and also examined tyrosine phosphorylation follow-
ing receptor stimulation. These studies revealed that the 5TM
isoform has a severe inability to activate adenylate cyclase and
produce cAMP. This was predicted due to deleted sequences
necessary for heterotrimeric G protein interaction. Of interest
was that when stimulated with secretin, the 5TM isoform
actually resulted in a significant reduction in the endogenous
cAMP levels (Fig. 6A). This could occur as a result of ligand-
induced activation of a phosphodiesterase [38]. Activation of
phosphodiesterase resulting in decreased cAMP production has
been previously described [39]. Furthermore, this effect on
cAMP by secretin suggests that if phosphodiesterase is
activated, it must be through a G-protein-coupled-independent
mechanism. There are a number of reports of G-protein-
independent signaling mechanisms [40–42]. Indeed, despite
lack of G protein binding, the 5TM isoform was able to activate
Fig. 6. Differential signal transduction of 7TM and 5TM VPAC1 receptors. (A) 105 CHO Flp-In cells/ml stably expressing 7TM or alternatively spliced 5TM VPAC1
receptor were untreated (control) or treated with 50 μM VIP or secretin for 30 s. cAMP production was measured by EIA. (B) 3×106 CHO Flp-In cells expressing
either 7TM or 5TM VPAC1 were serum starved overnight and then stimulated with 50 μMVIP or secretin for 30 min at 37°C. Cells were washed with PBS and lysed
in RIPA lysis buffer. Western blot analysis of total cell lysates after SDS–PAGE using anti-phosphotyrosine antibody is presented. Molecular size markers are indicated
on the right. Arrows indicate positions of phosphotyrosine proteins of interest. Western blot for β-actin served as loading control.
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independent of heterotrimeric G protein activation. Indeed,
previous investigators have reported tyrosine kinase-dependent,
G-protein-coupled-independent signaling pathways [43]. Thus,
our results suggest that a different signaling pathway(s) that
involves G-protein-independent mechanisms may be associated
with the 5TM isoform. Our results contrast with a previous
report showing that a 5TM isoform of CCR5 had no effect on
receptor activation compared to 7TM [30]; however, this may
be due to the fact that the 5TM isoform in this study continued
to retain the ability to bind G proteins.
Our observation that these isoforms of VPAC1 and VPAC2
are differentially expressed in various cell types is of particular
interest. It is intriguing to speculate that since these receptors
have differential signaling, their differential expression, parti-
cularly in malignant cells, could have biological significance.
Indeed, it is known that VPAC receptors can be overexpressed in
certain cancers and that stimulation of VPAC receptors on cancer
cells can increase their growth rate [44,45]. Our findings that
5TM isoforms of VPAC1 or VPAC2 may be found in malignant
cells raises the intriguing possibility that expression of the 5TMisoform on cancer cells, as it binds ligand but does not activate
adenylate cyclase, may compete with the 7TM isoform, as has
previously been suggested for IL-4 production with mouse
VPAC2 variants [35]. Thus, further study of the expression of
the 5TM isoform in various cancers is warranted. It is also very
curious that in cord blood there was no evidence of a 5TM
isoform of either VPAC1 or VPAC2; however, in adult human
PBMCs both isoforms were clearly found, with VPAC2
isoforms requiring cell activation for optimal expression.
These data have identified and characterized the region of
specific alternative splicing of the first human examples of a
5TM isoform of both VPAC1 and VPAC2. We have shown the
differential expression of these splice variants in both primary
human peripheral blood cells and various transformed cell lines,
including malignant cancer-derived cell lines. Finally, we have
demonstrated differential signaling of the 5TM isoform
compared to the 7TM form. Taken together, our findings
provide valuable knowledge of 5TM isoforms of VPAC
receptors and suggest these have biological relevance. Further
studies are currently under way to elucidate better their potential
role in biological processes.
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Cells
Cell lines used in this study were obtained from the American Type Culture
Collection (Manassas, VA, USA). CHO Flp-In cells were purchased from Gibco
(Burlington, ON, Canada). Whole blood was obtained through the Canadian
Blood Services from normal volunteers after they consented to donate blood.
PBMCs were isolated from whole blood using a Ficoll–Hypaque density
gradient. Nonadherent cells were cultured in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal bovine serum (FBS; Sigma, Canada) and 0.1%
gentamicin. The cultures were maintained at 37°C in a humidified atmosphere
of 5% CO2 and 95% air, at a density of 10
6 cells/ml by addition of culture
medium every other day. Adherent cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco BRL), supplemented with 10% FBS
and 100 units/ml each penicillin and streptomycin and grown in 5% CO2 and
95% air at 37°C. CHO Flp-In cells were grown in HAM F-12 nutrient mixture
(Gibco) containing 10% FBS and 0.125% hygromycin. The cultures were
maintained at 37°C in a fully humidified atmosphere of 5% CO2 and 95% air, at
a density of 106 cells/ml by addition of culture medium every other day. The
viability of all cells was confirmed by trypan blue exclusion (viability >96%)
prior to experiments.
cDNA cloning and sequencing
For cloning of full-length VPAC1 and VPAC2, mRNAs were isolated from
normal human primary cells and the Sup-T1 cell line, respectively, using the
QuikPrep Micro mRNA purification kit (Amersham Pharmacia Biotech, Inc.
Canada). Reverse transcription was accomplished using the First-Strand cDNA
synthesis kit (Amersham Pharmacia Biotech) according to the manufacturer’s
directions with the exception that a mixture of three oligo(dT) primers was used
as the first-strand primer containing a C, A, or G at the 3′ position [46]. PCR was
performed in a Perkin–Elmer GeneAmp PCR 9700 thermocycler and reactions
contained 1× Olerup SSP PCR Master Mix with 1 unit of Taq polymerase
(Genovison, Inc., West Chester, PA, USA), 25 μM forward and reverse primers,
and 2 μl of template cDNA described above, plus a no-template control, in 25-μl
volumes. After initial denaturation at 95°C for 2 min, 35 cycles of amplification
were carried out at 94°C for 1 min, 60°C for 1 min, 72°C for 1 min, with a final
extension step of 7 min at 72°C. The nucleotide sequences of oligonucleotide
primers used for the PCR were designed based on the published sequences
(GenBank database Accession No. L13288, VPAC1, Sense F, 5′-CTCAGGG-
CAGACCATGCGCCCGCCA-3′, and Antisense R, 5′-CAGACCAGGGA-
GACTTCGGCTTG-3′, corresponding to, respectively, nt 82–106 and 1467–
1445 of the VPAC1 receptor; and Accession No. L36566, VPAC2, Sense F, 5′-
CACGCTGAGCTCGGGATGCGGA-3′, and Antisense R, 5′-AGATGACC-
GAGGTCTCCGTTTG-3′, corresponding to nt 147–168 and 1477–1456,
respectively). The sense and antisense primer pairs used were specific for the
amplification of the full-length VPAC receptors as well as the TM5–7 domains
and C-terminus regions. Following PCR amplification, 20 μl of PCR product
was subjected to electrophoresis on a 1.5% agarose gel and stained with
ethidium bromide. The DNA fragments obtained were purified by using the
QIAquick gel extraction kit (Qiagen, Inc., Mississauga, ON, Canada) and then
cloned directly into the pCR2.1-TOPO vector (Invitrogen Canada, Inc.,
Burlington, ON, Canada). All of the positive clones with a cDNA insert that
potentially contained multitranscripts of VPAC1 and VPAC2 were sequenced by
the dideoxy method using reagents (Amersham Pharmacia Biotech) with the T7
and M13 primers. The sequences for VPAC1 and VPAC2 were analyzed using
the software DNASIS Max 2.0 and BLAST in the GenBank database.
Construction of stable VPAC-expressing cell lines
The cDNAs encoding both full-length wild-type human VPAC1 receptor
and the 5TM variant truncated isoform were excised from the above TA cloning
vectors by digestion with BglII and XbaI and inserted into the BamHI and XbaI
sites of the mammalian expression vector pcDNA3.1 (Invitrogen), which
contains an Xpress-tag insert. CHO cells were selected for transfection as these
cells do not express VPAC1 mRNA, although VPAC2 mRNA was detected(data not shown). CHO cells were plated in 100-mm dishes (4×106 cells/dish)
and transfected with 10 μg of the recombinant plasmid containing the wild-type
and variant VPAC1 receptors or pcDNA3.1 empty vector by using the CaPO4
precipitation method. Transfected cells were grown in culture medium (DMEM)
supplemented with 10% (v/v) heat-inactivated FBS, 10 μg/ml gentamicin, and
1% L-glutamine in a fully humidified atmosphere of 95% air and 5% CO2 at
37°C. Resistant cells were selected by addition of Geneticin (G418) to a final
concentration of 0.5 mg/ml. After 10–15 days of selection, individual colonies
were isolated under limiting dilution in 96-well microtiter plates and grown until
confluence, trypsinized, and further expanded in six-well microtiter plates. The
cell clones expressing the different recombinants were selected and used for
subsequent studies. Alternatively, the DNA fragments encoding both 7TM and
5TM VPAC1 were double digested and subcloned into the pcDNA5/FRT vector
(Invitrogen). Briefly, the HindIII–XhoI fragment from the TA vectors, which
contain DNA segments that encode 7TM/5TM VPAC1, were subcloned
individually into pcDNA5/FRT (Invitrogen). The resulting plasmids were
cotransfected along with pOG44 into CHO Flp-In cells (Invitrogen) to induce a
site-specific integration event. Stable integrants were then screened. For
verification of the expression of the 7TM and 5TM human VPAC1 receptor
in the transfected cells, 1 μg of purified mRNA from transfected cells was used
for cDNA synthesis. RT-PCR was carried out with specific VPAC1 receptor
primers and analyzed as described above.
RT-PCR for detection of VPAC transcripts
For identification of splice-variant isoforms of both VPAC1 and VPAC2
receptors in different human cells, total RNA was isolated with the TRIzol
reagent (Invitrogen) according to the manufacturer’s recommendations. Two
micrograms of RNAwas subjected to reverse transcription with the First-Strand
cDNA synthesis kit (Amersham Pharmacia Biotech) according to the
manufacturer’s directions, with the exception that a mixture of three oligo(dT)
primers was used as the first-strand primer containing a C, A, or G at the 3′
position [46]. The cDNAwas amplified by either PCR or nested-PCR with the
same reagents and the following primers: VPAC1, 5′-TGCTTGCC-
GTCTCCTTCTTCTCT-3′ (sense) and 5′-GATCCTGGTGGTCAGACCAGG-
GAGA-3′(antisense), corresponding to nt 822–844 and 1479–1455 of the
VPAC1 receptor (Accession No. L13288); VPAC2, first-round PCR, 5′-
GTACTGCATCATGGCCAAC-3′ (sense) and 5′-GTGGGCCTC-
CCGCCGCGTCC-3′ (antisense) corresponding to nt 792–810 and 1516–1497
of the VPAC2 receptor (Accession No. L36566); and nested-PCR, 5′-
CCCTAGAAGGTGCTTCCTGG-3′ (sense) and 5′-GATGTCTCTAGAT-
GACCGAGGTCTCCGTTTG-3′ (antisense), corresponding to nt 870–889 and
1479–1456. The products spanned 658 (VPAC1, 7TM), 394 (VPAC1, 5TM), 610
(VPAC2, 7TM), and 388 bp (VPAC2, 5TM).
Southern blot
For confirmation of PCR products corresponding to the expected 7TM and
5TM of VPAC2 receptor transcripts, DNA fragments were separated on 1.5%
agarose gel and transferred onto Nybond-N+ nylon membrane (Amersham
Biosciences). Southern blotting of DNA was performed according to the
protocol (PT1190-1) from Clontech Laboratories, Inc. As hybridization probes,
we used the 1.46-kb full-length VPAC2 derived from Sup-T1 cells and the DNA
sequence based on the published sequence (GenBank database Accession No.
L136566). The DNA probes were labeled using [32P]dCTP (Amersham) by
random priming using the Multiprime DNA labeling system (Amersham
Pharmacia Biotech) according to the manufacturer’s directions. The membrane
was washed with hybridization washing buffer and then exposed to X-ray film
(Hyperfilm MP).
Metabolic labeling
To show the 7TM and 5TM VPAC1 cDNA result in protein expression, we
used metabolic labeling of newly synthesized proteins by 35S-labeled amino
acids as previously described [45,46]. Briefly, 100-mm plates of confluent CHO
cells transfected using the pcDNA3.1 vector were starved of cysteine (Cys) and
methionine (Met) for 1 h and then incubated at 37°C in Cys- and Met-free
799P.B. Bokaei et al. / Genomics 88 (2006) 791–800medium (Sigma–Aldrich Chemical, Oakville, ON, Canada) containing
0.25 mCi each of 35S-labeled Met and Cys (1175 and 1075 Ci/mmol sp act,
respectively; ICN, Costa Mesa, CA, USA) for 4 h. Following incubation, cells
were washed with cold PBS and lysed in ice-cold RIPA lysis buffer (1% Nonidet
P-40, 0.1% SDS, 0.1%Na3 deoxycholate, 50 mmol/L Hepes, pH 7.3, 150 mmol/
L NaCl, 2 mmol/L sodium orthovanadate, 50 μmol/L ZnCl2, 2 mmol/L EDTA,
50 μM/L NaF, 50 μM orthophosphate, 2 mmol/L phenylmethylsulfonyl
fluoride) for 10 min on ice. The lysate was precleared twice by adding it to
unconjugated protein A–Sepharose CL4 B beads (Amersham Bioscience) with
rotation for 1 h. The precleared lysate was then incubated for 2 h with anti-
Xpress antibody that had been prebound to protein A–Sepharose beads. The
beads were washed and boiled in reducing sample buffer, and the 35S-labeled
proteins were separated on SDS–PAGE. The gel was fixed in 7% acetic acid for
15 min followed by soaking for 30 min in Amplify (Amersham Bioscience). The
gel was dried on a Bio-Rad Model 583 gel dryer at 80°C for 2 h and allowed to
expose film (Kodak BioMax MR) by autofluorography.
Cyclic AMP assay
The biological activity of 7TM and 5TM human VPAC1 receptors was
assessed by their ability to elicit intracellular cAMP generation in response to
VIP and secretin stimulation. In summary, the transfected Flp-In CHO cells (105
cells/ml in 100-μl volumes) were grown in 96-well microtiter plates overnight.
To measure the cAMP accumulation, cells were then stimulated with 50 μMVIP
or 50 μM secretin for 30 s at 37°C. The medium was aspirated, cells were lysed,
and cAMPwas quantified by using a cAMP enzyme immunoassay (EIA) system
(Amersham Pharmacia Biotech), following the manufacturer’s instructions.
Western blot analysis
To determine the effect of ligand stimulation on tyrosine phosphorylation,
Flp-In CHO cells (3×106) transfected with either the 7TM or the 5TM form
of VPAC1 were serum starved overnight and stimulated with 50 μM VIP or
secretin for 30 min at 37°C. Following the treatment, cells were washed twice
with ice-cold PBS and then lysed in RIPA lysis buffer for 10 min on ice.
After centrifugation, cell lysates were mixed with SDS sample buffer and
boiled. Proteins were separated by 10% SDS–PAGE and blotted onto
nitrocellulose membranes. The membranes were blocked for 1 h at room
temperature using Tris-buffered saline (TBS) containing 0.8% BSA (Bioshop,
Burlington, ON, Canada) plus 0.045% fish gelatin (Sigma–Aldrich). The
membranes were washed in TBS–Tween 20 and then incubated for 2 h with
monoclonal anti-phosphotyrosine antibody (4G10; Upstate Biotechnology,
Inc., Lake Placid, NY, USA), washed, and then incubated with goat anti-
mouse IgG conjugated to horseradish peroxidase (Bio-Rad, Mississauga, ON,
Canada) followed by enhanced chemiluminescence (Bioscience Corp., Baie
D’Urfé, QC, Canada) used to visualize the proteins. Membranes were
stripped (30 min at 50°C using 100 mM 2-mercaptoethanol and 2% SDS in
62.5 mM Tris–HCl, pH 6.9) and then reprobed using anti-β-actin (Sigma–
Aldrich) to control for loading.Acknowledgment
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